Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Mesalamine (5-aminosalicylic acid, Apriso) Clear all

Conditions: Ulcerative Colitis
Interventions: SPD476, Asacol; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Bristol, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: HIV-1-infection, Gut Inflammation
Interventions: Pentasa vs Align; Drug
Lead sponsor: AIDS Healthcare Foundation; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ulcerative Colitis
Interventions: mesalamine; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 44
States / cities: Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more

Conditions: Crohn´s Disease
Interventions: Pentasa, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: San Diego, California • Clearwater, Florida • John's Creek, Georgia + 4 more

Conditions: Ulcerative Colitis
Interventions: Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine); Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 54
States / cities: Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more

Conditions: Ulcerative Colitis
Interventions: MMX Mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Long Beach, California + 53 more

Conditions: Ulcerative Colitis
Interventions: Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg; Procedure · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more

Conditions: Colitis, Ulcerative
Interventions: Low-dose MH002, High-dose MH002, Placebo; Drug
Lead sponsor: MRM Health NV; Industry
Eligibility: 16 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more

Conditions: Ulcerative Colitis (Disorder)
Interventions: Hydroxychloroquine, Mesalamine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Ulcerative Colitis
Interventions: Mesalamine, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 18
States / cities: Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more

Conditions: Ulcerative Colitis
Interventions: Budesonide MMX®, Placebo, 5-ASA; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Anaheim, California • Lakewood, California • San Diego, California + 36 more

Conditions: Diverticulitis
Interventions: SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 46
States / cities: Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more

Conditions: Ulcerative Colitis
Interventions: 5 ASA, enemas, suppositories, corticosteroids; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more

Conditions: Healthy
Interventions: Amoxicillin + MMX placebo, Amoxicillin + MMX mesalazine/mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Ulcerative Colitis
Interventions: mesalamine, ALTH12-1:4, ALTH12-2:4; Drug
Lead sponsor: Altheus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Colitis, Ulcerative
Interventions: Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C; Biological
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more

Conditions: Ulcerative Colitis
Interventions: Asacol (mesalamine); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain Tumor
Interventions: Sulfasalazine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Beryllium Disease
Interventions: Mesalamine, Placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Ulcerative Colitis
Interventions: MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose); Drug
Lead sponsor: Shire; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 9
States / cities: Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more

Conditions: Healthy
Interventions: Mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions: Anal Pap smear and HPV DNA testing; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 310 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Inflammatory Bowel Diseases
Interventions: SHINGRIX; Biological
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

A Study With Pentasa in Patients With Active Crohn's Disease

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Confirmatory Clinical Study in Active Ulcerative Colitis

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Prevention of Recurrence of Diverticulitis

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Determination of the Optimal Treatment Target in Ulcerative Colitis

Asacol Dosing Study for Active Ulcerative Colitis

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

Targeting Oxidative Stress in Chronic Beryllium Disease

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib